| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M D Muenter, J E Ahlskog, G Bell, P McMani. PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent. Neurology. vol 38. issue 10. 1988-10-27. PMID:2901697. |
side effects were similar to those of other dopamine agonists but dyskinesia was seen in only one patient. |
1988-10-27 |
2023-08-11 |
Not clear |
| P Falardeau, S Bouchard, P J Bédard, R Boucher, T Di Paol. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. European journal of pharmacology. vol 150. issue 1-2. 1988-09-16. PMID:3261249. |
these results suggest that stimulation of d-1 and d-2 dopamine receptors can differently influence the mechanisms controlling dopamine agonist-induced dyskinesia in mptp-treated monkeys. |
1988-09-16 |
2023-08-11 |
monkey |
| T Brücke, K Bankiewicz, J Harvey-White, I Kopi. The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model. European journal of pharmacology. vol 148. issue 3. 1988-08-11. PMID:3260191. |
the partial dopamine agonist terguride (transdihydrolisuride) administered to four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) lesioned hemiparkinsonian monkeys (at a dose of 4 mg/kg orally) induced marked contralateral turning that lasted 3.5 h. the 6-n-propyl derivative of terguride (proterguride) given to two monkeys (at a dose of 0.4 mg/kg orally) caused contralateral turning which lasted for more than 24 h but produced side effects such as dyskinesia and stereotype. |
1988-08-11 |
2023-08-11 |
monkey |
| E Schneide. [Parkinson disease--new aspects of therapy]. Wiener medizinische Wochenschrift (1946). vol 138. issue 3. 1988-06-17. PMID:3285599. |
the occurrence of long-term complications such as fluctuations of mobility (on/off phenomena) and dyskinesias caused the use of lower levodopa doses and the simultaneous application of other antiparkinson drugs, e. g. anticholinergics, amantadines, dopamine agonists and mao-b-inhibitors. |
1988-06-17 |
2023-08-11 |
Not clear |
| E Toth, A Lajth. 3-Mercaptopropionic acid administration into the caudate-putamen of the rat provokes dyskinesia. Pharmacology, biochemistry, and behavior. vol 29. issue 3. 1988-06-09. PMID:3362946. |
striatal gaba and dopamine were decreased and the dopamine metabolites 3,4-dihydroxyphenylacetic and homovanillic acid were increased on the mpa-injected side at 2-10 min after the onset of dyskinesia. |
1988-06-09 |
2023-08-11 |
rat |
| C N Karso. Physiology of normal and abnormal blinking. Advances in neurology. vol 49. 1988-04-07. PMID:2964173. |
nevertheless, insofar as blink rate represents a noninvasive probe of cns dopamine activity, the failure to associate dyskinesias (except levodopa-induced dyskinesia) with increased blinking, indicates that the pathophysiology of these conditions may not involve hyperactivity of cns dopamine systems. |
1988-04-07 |
2023-08-11 |
Not clear |
| N Panagopoulos, N A Matsokis, T Valcan. Kinetic and pharmacologic characterization of dopamine binding in the mouse cerebellum and the effects of the reeler mutation. Journal of neuroscience research. vol 19. issue 1. 1988-03-25. PMID:3343704. |
the purpose of this study was to characterize the dopaminergic system in the mouse cerebellum and to determine whether the dyskinesia of the reeler mutant is accompanied by alterations in cerebellar and/or striatal dopamine binding. |
1988-03-25 |
2023-08-11 |
mouse |
| M el-Awar, M Freedman, P Seeman, L Goldenberg, J Little, P Solomo. Response of tardive and L-dopa-induced dyskinesias to antidepressants. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. vol 14. issue 4. 1988-02-10. PMID:3690436. |
the response of the dyskinesias to antidepressant medication may be due to the fact that antidepressants decrease beta-adrenoreceptor sensitivity and density which in turn may result in a diminished release of dopamine since beta-adrenoceptors mediate the noradrenaline-stimulated release of dopamine. |
1988-02-10 |
2023-08-11 |
Not clear |
| T Ohmot. Experimental study on resting tremor and L-dopa-induced dyskinesia. European neurology. vol 26 Suppl 1. 1987-07-10. PMID:2953603. |
the administration of l-dopa or dopamine agonists relieved them and followingly induced dyskinesias. |
1987-07-10 |
2023-08-11 |
monkey |
| P J Bédard, T Di Paolo, P Falardeau, R Bouche. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain research. vol 379. issue 2. 1986-10-06. PMID:3488796. |
we therefore believe that l-dopa and bromocriptine affect denervated postsynaptic dopamine receptors differently, that bromocriptine is less likely to induce agonist supersensitivity and that this probably explains the lesser tendency to induce dyskinesia after chronic treatment. |
1986-10-06 |
2023-08-11 |
monkey |
| H Rosengarten, J W Schweitzer, A J Friedhof. Selective dopamine D2 receptor reduction enhances a D1-mediated oral dyskinesia in rats. Life sciences. vol 39. issue 1. 1986-08-14. PMID:3523096. |
selective dopamine d2 receptor reduction enhances a d1-mediated oral dyskinesia in rats. |
1986-08-14 |
2023-08-11 |
human |
| V Lepore, N Di Reda, G Defazio, D Pedone, A Giovine, C Lanzi, B Tartaglione, P Livre. Dopaminomimetic action of diphenylhydantoin in rat striatum: effect on homovanillic acid and cyclic AMP levels. Psychopharmacology. vol 86. issue 1-2. 1985-09-25. PMID:2991966. |
diphenylhydantoin (dph) is known to induce reversible paroxysmal dyskinesias and paranoid psychosis in humans, but its interactions with dopamine (da) metabolism are not clear. |
1985-09-25 |
2023-08-11 |
rat |
| K G Lloyd, M T Willigens, M Goldstei. Induction and reversal of dopamine dyskinesia in rat, cat, and monkey. Psychopharmacology. Supplementum. vol 2. 1985-07-24. PMID:2987905. |
induction and reversal of dopamine dyskinesia in rat, cat, and monkey. |
1985-07-24 |
2023-08-11 |
rat |
| K G Lloyd, M T Willigens, M Goldstei. Induction and reversal of dopamine dyskinesia in rat, cat, and monkey. Psychopharmacology. Supplementum. vol 2. 1985-07-24. PMID:2987905. |
in the rat only stereotyped movements were observed, whereas in the cat dopamine agonists (apomorphine) preferentially induced dyskinesia but dopamine/noradrenaline uptake inhibitors (d-amphetamine, nomifensine) induced predominantly stereotypes; l-dopa induced an equal, low, number of both kinds of movements in the cat. |
1985-07-24 |
2023-08-11 |
rat |
| K G Lloyd, M T Willigens, M Goldstei. Induction and reversal of dopamine dyskinesia in rat, cat, and monkey. Psychopharmacology. Supplementum. vol 2. 1985-07-24. PMID:2987905. |
in the monkey with bilateral lesions of the nigrostriatal dopamine pathways the aims could be divided into type 1 dyskinesia (behavioral), type 2 dyskinesia (oral and psychomotor), and chorea. |
1985-07-24 |
2023-08-11 |
rat |
| K G Lloyd, M T Willigens, M Goldstei. Induction and reversal of dopamine dyskinesia in rat, cat, and monkey. Psychopharmacology. Supplementum. vol 2. 1985-07-24. PMID:2987905. |
these studies are parallel to and support the clinical observations that dyskinetic movements following a direct action at the dopamine receptor (tardive dyskinesia) may be reversed by progabide whereas those associated with dopamine neuron activity, perhaps together with noradrenergic activation (l-dopa dyskinesia), are resistant to the antidyskinetic action of progabide. |
1985-07-24 |
2023-08-11 |
rat |
| K Fuxe, L Agnati, F Mascagni, S Kuga, E Helmer-Matyjek, M Goldstei. Central dopamine agonist activity on the 8-alpha-amino-ergoline CU 32-085. Brain research. vol 328. issue 2. 1985-05-31. PMID:3986530. |
studies in monkeys with ventromedial tegmental lesions suggest that cu 32-085 might be an effective antiparkinsonian agent which produces less dyskinesias than the other tested dopamine agonists. |
1985-05-31 |
2023-08-11 |
mouse |
| B Costall, M E Kelly, R J Naylo. The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent. British journal of pharmacology. vol 83. issue 3. 1985-01-31. PMID:6542444. |
the antidyskinetic action of dihomo-gamma-linolenic acid (dhla) was assessed against dyskinesias induced in the guinea-pig by dopamine injected into the striatum (200 micrograms bilateral 2 h after nialamide, 75 mg kg-1, i.p.) |
1985-01-31 |
2023-08-12 |
rat |
| B Costall, M E Kelly, R J Naylo. The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent. British journal of pharmacology. vol 83. issue 3. 1985-01-31. PMID:6542444. |
and in the guinea-pig and rat by 2-di-n-propylamino-5, 6-dihydroxytetralin (tetralin), 0.025 mg kg-1, s.c. dopamine and tetralin-induced dyskinesias in the guinea-pig were reduced or abolished by dhla given i.p., 30-100 mg kg-1, given once daily for 5-10 days. |
1985-01-31 |
2023-08-12 |
rat |
| S Korsgaard, U Noring, J Gerlac. Fluperlapine in tardive dyskinesia and parkinsonism. Psychopharmacology. vol 84. issue 1. 1984-12-18. PMID:6149595. |
fluperlapine, a new clozapine-like neuroleptic drug with weak affinity for dopamine receptors, was evaluated in a blind, placebo controlled trial in 11 patients with stable hyperkinesia (ten with tardive dyskinesia (td) and one with spontaneous dyskinesia). |
1984-12-18 |
2023-08-12 |
Not clear |